Palliative care consultation linked to reduced direct hospital costs
1. In this meta-analysis of available studies, early palliative care consultation (PCC) for patients admitted to hospital with serious illness was associated with a reduction in direct hospital costs for that admission.
2. The reduction in direct hospital costs was greater for those patients with a cancer diagnosis and for those with 4 or more comorbidities.
Study Rundown: Use of high-cost health care interventions is common amongst patients with serious disease conditions admitted to acute care hospitals. Palliative care interventions have been hypothesized to aid in directing care to be congruent with patient goals of care and reduce ineffectual interventions. The current study was a meta-analysis of available data which evaluate the change in direct healthcare costs associated with early palliative care consultation. The study found that PCC was associated with a reduction in direct hospital costs, and this effect was greater for those with a cancer diagnosis or with a greater number of comorbidities.
The study demonstrates that improved access to PCC and palliative interventions may be effective in reducing health care costs amongst those with serious illness. The minority of patients with serious illness admitted to hospital in this study received PCC and changes in policy and administration are needed to improve access to PCC. The study has many strengths including its multi-centre data sources and inclusion of time to consultation as an important determinant of effectiveness of the intervention. The main limitations of the study include the reliance on retrospective data, and lack of inclusion on other health care costs including out-of-pocket and outpatient costs.
In-Depth [meta-analysis]: This study is a meta-analysis of studies identified using a systematic search of published studies that reported direct hospital costs associated with palliative care consultation. Patients were included if they had 1 of 7 serious illnesses (cancer; heart, liver, or kidney failure; chronic obstructive pulmonary disease; AIDS/ HIV; or selected neurodegenerative conditions) and were admitted to an acute care hospital. Patients were excluded if they were admitted with trauma, or had a history of organ transplant. Studies were excluded if data were not available for outcome measures.
A total of 6 studies were included in the meta-analysis encompassing 133 118 patients, of whom 3.6% had a PCC within 3 days of admission. For all patients included in the study, PCC was linked to a reduction of direct hospital cost of −$3237 (95%CI, −$3581 to −$2893; p < 0.001). Patients with a diagnosis of cancer had a reduction of −$4251 (95%CI, −$4664 to −$3837; p < 0.001) while non-cancer patients had a change of −$2105 (95%CI, −$2698 to −$1511; p < 0.001). The reduction in cost was also observed to be greater for those with more than 4 major comorbidities than those with 2 or fewer.
©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML